Editor's note

This ExpertREACT article was originally published on 26 January 2009. M&A details and market positions described reflect the state of knowledge at that date.

The $68bn deal that reshaped vaccines

On 26 January 2009, Pfizer announced a definitive merger agreement to acquire Wyeth in a cash-and-stock transaction valued at $50.19 per share - a total of approximately $68bn. The deal was remarkable in scale and in what it delivered for Pfizer's vaccine ambitions. Wyeth Pharmaceuticals' 2008 revenues included approximately 10% from Prevnar (PCV-7), which had recorded $2.7bn in sales - an 11% increase on 2007. The deal gave Pfizer, which had previously made only selected smaller vaccine investments (Powdermed, Coley, Cytos), sudden access to the world's best-selling vaccine franchise. The newly enhanced 13-valent successor PCV-13 was already filed in both the US and EU, representing a clear near-term commercial catalyst.

Wyeth's vaccines history was colourful. Originally Wyeth-Lederle, the company had consistently been among the leading vaccine companies since 2000 despite having a narrower portfolio than rivals GSK, Sanofi Pasteur and Merck. Historically Wyeth had marketed Rotashield (withdrawn in 1999 for intussusception) and Flushield (withdrawn due to lack of demand), but had built an enviable position through Prevnar. The company had also entered into several exploratory biotech-research alliances in recent years. Shortly before the Pfizer deal was announced, Wyeth had itself been in discussions with Netherlands-based Crucell regarding a possible acquisition - conversations that were terminated when the larger Pfizer offer emerged.

Prevnar (PCV-7) revenues FY 2008
$2.7bn
An 11% increase on 2007; Wyeth's PCV-13 successor was already filed in US and EU at the time of the Pfizer acquisition announcement

Implications for the competitive landscape

VacZine Analytics identified the Pfizer-Wyeth merger as a potentially transformative event for the pneumococcal vaccine category specifically and the broader vaccine competitive landscape generally. With PCV-13 expected to succeed PCV-7 and potentially gain adult indications, the merged entity would have a sustained high-value vaccine revenue platform. Remaining competitors in pneumococcal vaccines - primarily GSK Biologicals with Synflorix - would need to accelerate their own positioning strategies. The deal also raised broader strategic questions about how quickly Pfizer would seek to organically or inorganically build out a broader vaccine pipeline around the pneumococcal cornerstone.